Reversible posterior leukoencephalopathy syndrome and anti-neoplastic agents: a review

Shah-Khan, Farheen; Pinedo, Daryl; Shah, Prabodh

doi:10.4081/150

Cited by 2 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…No single antineoplastic agent has been consistently associated with PRES, but high-dose, multidrug chemotherapy is more frequently associated.,[9] which is characteristically seen in our case.…”

Section: Discussionsupporting

confidence: 73%

Gemcitabine and Cisplatin induced posterior reversible encephalopathy syndrome: A case report with review of literature

Kabre

Kamble

2016

J Res Pharm Pract

View full text Add to dashboard Cite

Posterior reversible encephalopathy syndrome (PRES) is a recently described, scarcely documented clinical entity. PRES is caused by various factors, the most common being hypertension, followed by nonhypertensive causes such as renal diseases and immunosuppressive therapy. Recently, some cases have been reported about the association of increased use of cytotoxic and immunosuppressive agents in cancer patients, and relevant reports have increased with advances in radiological examinations. Here, we report a case of gallbladder cancer with liver metastasis undergoing gemcitabine- and cisplatin-based chemotherapy who presented with complaints of seizures, headache, and bilateral lower limb weakness. Thorough clinical examination, biochemical analysis, and radiological evaluation led to diagnosis of PRES. It is important to recognize this syndrome which will facilitate early diagnosis and prompt symptomatic management. Removal of causative agent is an important aspect of management. Studies are needed to identify factors of adverse prognostic significance and to develop neuroprotective strategies.

show abstract

Section: Discussionsupporting

confidence: 73%

Gemcitabine and Cisplatin induced posterior reversible encephalopathy syndrome: A case report with review of literature

Kabre

Kamble

2016

J Res Pharm Pract

View full text Add to dashboard Cite

show abstract

“…It has been reported with therapy with immunosuppressants, notably cyclosporine, tacrolimus, and mycophenolate, but also cytotoxic agents (cyclophosphamide, cisplatin, carboplatin, bleomycin, vinblastine, adriamycin, cytarabin, methotrexate, and L-asparaginase). 5 Characteristic neuroradiologic features are cerebral white matter lesions, which can typically involve the occipital, temporal, and parietal cortex but may also affect the brainstem, cerebellum, and basal ganglia. We report the case of a patient with PRES suffering from metastatic squamous cell carcinoma of the penis treated with the anti-epidermal growth factor receptor (EGFR) monoclonal antibody, cetuximab, which remitted without sequelae after cetuximab discontinuation.…”

mentioning

confidence: 99%

Nonconvulsive Status Epilepticus Related to Posterior Reversible Leukoencephalopathy Syndrome Induced by Cetuximab

Palma¹,

Gómez‐Ibáñez²,

Martín³

et al. 2011

The Neurologist

View full text Add to dashboard Cite

show abstract

Reversible posterior leukoencephalopathy syndrome and anti-neoplastic agents: a review

Cited by 2 publications

References 0 publications

Gemcitabine and Cisplatin induced posterior reversible encephalopathy syndrome: A case report with review of literature

Gemcitabine and Cisplatin induced posterior reversible encephalopathy syndrome: A case report with review of literature

Nonconvulsive Status Epilepticus Related to Posterior Reversible Leukoencephalopathy Syndrome Induced by Cetuximab

Contact Info

Product

Resources

About